Q1 2026 Management view “The start of the year has been an eventful one for MiMedx as we navigated the new reimbursement dynamics and continue to leverage growth opportunities for the company,” said ...
Ecopipam, Emalex's investigational asset for pediatric Tourette syndrome (TS), is a first-in-class selective dopamine D1 receptor antagonist with FDA Orphan Drug and Fast Track designations. The late- ...
A serendipitous meeting at a blues club in 2017 led to a unique partnership.
Learn how to spot a legitimate tax relief company, including key signs of trustworthiness and red flags that could signal a ...
More affordable housing is coming to Elk Grove, and a lottery is now open for interested residents. The Pardes, an affordable ...
In March, officials with the N.C. Department of Health and Human Services announced a $1.5 million expansion of LEAD programs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results